Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. The studies were reported simultaneously ...

HOUSTON ― Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge. A recent review published in Genes & Diseases offers a comprehensive ...

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in ...

Retrospective cohort study of patients with ATC and at least one ctDNA drawn before systemic therapy start (referred to as baseline) between February 2021 and August 2024. ctDNA was correlated with ...

Scientists from Wuhan University and affiliated organizations have published findings from their investigation into the role of Yes-associated protein (YAP), which is a critical effector of the Hippo ...

A retrospective study of pyrotinib for advanced salivary duct carcinoma (SDC) with positive HER2 expression. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

Bengaluru: Thyroid cancer can easily be missed at the beginning stages. There are no dramatic signals - only small, subtle ...

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer ...